



> **The Company**

CytRx Corporation is a world leading biopharmaceutical company engaged in the development of crucial health care therapeutics. The company is positioned as an innovative clinical stage company with three oral drug candidates in its pipeline, a library of 500 small molecule drug candidates, and an extended patent portfolio. The company's products have the potential of moving into markets of vast proportions, making major contributions in combating ALS (Lou Gehrig's disease), obesity, Type 2 diabetes, CMV (Cytomegalovirus), HIV, muscular dystrophy, cancer, and spinal cord injuries.

> **Products**

CytRx has a number of exclusive licensing agreements, including a proprietary portfolio of applications for gene silencing (RNAi) technology in the areas of obesity and Type 2 diabetes. The company also has an exclusive, worldwide royalty bearing agreement to use RNAi gene silencing technology in the development of an ALS treatment. Two such products are Arimoclomol and Bimoclomol (used to treat ALS and Type 2 diabetes).

CytRx has also licensed the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology. The HIV vaccine is based on a unique cocktail of human HIV-1 primary isolates from several genetic subtypes of HIV.

CytRx is focused on developing its RNAi technology for the treatment of Lou Gehrig's disease (ALS) and CMV and is also utilizing it as a discovery tool for small molecule drugs in obesity and Type 2 diabetes.

The technology uses ribonucleic acid to selectively turn off the harmful genes of infectious viruses or malignant tumor cells — thus treating diseases by eradicating or repairing abnormal disease causing proteins. If even a fraction of RNAi's promise is realized, the technology could lead to billions of dollars in new drugs. This has prompted many prominent scientists to name its discovery the most important scientific breakthrough in decades. Other CytRx products include Iroxanadine to treat cardiovascular disease diabetic complications, FLOCOR for Sickle Cell Disease, Optivax (conventional vaccine delivery), and TranzFect (DNA Vaccine Delivery).

> **Management Team**

CytRx is led by a strong management and advising team. STEVEN A. KRIEGSMAN, President and Chief Executive Officer, previously served as director and Chairman of Global Genomics Capital LLC. He is Chairman and founder of TKG, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies. Mr. Kriegsmann serves as a director of Bradley Pharmaceuticals, Inc.

DR. LOUIS IGNARRO, Scientific Advisory Board Chair and Board member, is a Nobel Laureate in Medicine and also a Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. Dr. Ignarro has received countless awards for his work in medicine and as a professor.

The Scientific Advisory Board includes experts in the fields of medicine, genetics, biotechnology, RNAi, cell biology, finance and strategic partnering. Members of the Board include world leaders in the fields of obesity and Type 2 diabetes.

> **Opportunity**

- Huge market size — RNAi's technology has potential to lead to billions of dollars in new drugs serving vast markets.
- Balanced portfolio of novel RNAi and conventional small molecule drug development. Dual-path therapeutics development strategy combining small molecule and RNAi approach to treat disease.
- ALS Phase II trial of Arimoclomol planned for first half of 2005. Positive pre-clinical data showing potential to also treat Type 2 diabetes.
- Potential for orphan drug status.
- Positive pre-clinical data showing potential of Iroxanadine to treat cardiovascular disease.
- Exclusive worldwide rights to commercialize novel DNA-based HIV vaccine — ongoing Phase I trial.
- Novel and proprietary drug targets for obesity and Type 2 diabetes.
- Attractive risk-reward profile compared to peers.
- \$16 million awarded by US National Institutes of Health (NIH) specifically for Phase 1 study to evaluate this technology.
- Broad-based strategic alliance with University of Massachusetts Medical School to develop novel compounds for ALS, obesity, Type 2 diabetes and CMV using RNAi technology.

The financial markets are risky. Investing is risky. Past performance does not guarantee future performance. The foregoing has been prepared solely for informational purposes and is not a solicitation, or an offer to buy or sell any security. Offering made by Offering Memorandum only. Opinions are based on historical research and data believed reliable, but there is no guarantee that future results will be profitable. This does not purport to be a complete analysis of the Portfolio Company. The author has relied on information provided by sources deemed to be reputable and although believed to be true, cannot guarantee the accuracy of such information. All claims made by this brochure should be verified by the reader. This brochure is not intended to directly or indirectly provide advice as to the value of any offer described herein, or as to the advisability of investing in such offer. Investing is not suitable for everyone; you should know and understand the risk before making a decision.